Neurolixis Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $8.61M

  • Investors
  • 4

Neurolixis General Information

Description

Developer of novel drugs designed for treating human central nervous system diseases. The company's platform focused on the discovery and development of drugs for the treatment of nervous system disorders including Parkinson's disease, Autism Spectrum Disorders, depression, and pain, enabling the healthcare industry to have new treatments for nervous system disorders.

Contact Information

Website
www.neurolixis.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 251 Little Falls Drive
  • Wilmington, DE 19808
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 251 Little Falls Drive
  • Wilmington, DE 19808
  • United States
+1 (858)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurolixis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 08-Oct-2019 $8.61M Completed Startup
3. Grant 08-Aug-2014 Completed Startup
2. Angel (individual) 18-Jul-2013 $15K $15K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Neurolixis’s complete valuation and funding history, request access »

Neurolixis Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Neurolixis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230233539-A1 Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy Active 26-Jan-2022
US-11974992-B2 Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy Active 26-Jan-2022
AU-2023213071-A1 Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy Pending 26-Jan-2022
US-20200155535-A1 Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors Active 20-Jul-2017
US-11191758-B2 Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors Active 20-Jul-2017 A61K31/4545
To view Neurolixis’s complete patent history, request access »

Neurolixis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurolixis Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
United States Department of Defense Government
Michael J. Fox Foundation Limited Partner
Rett Syndrome Research Trust Other
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
To view Neurolixis’s complete investors history, request access »

Ready to get started?

Request a free trial

Neurolixis FAQs

  • When was Neurolixis founded?

    Neurolixis was founded in 2011.

  • Where is Neurolixis headquartered?

    Neurolixis is headquartered in Wilmington, DE.

  • What is the size of Neurolixis?

    Neurolixis has 8 total employees.

  • What industry is Neurolixis in?

    Neurolixis’s primary industry is Drug Discovery.

  • Is Neurolixis a private or public company?

    Neurolixis is a Private company.

  • What is Neurolixis’s current revenue?

    The current revenue for Neurolixis is .

  • How much funding has Neurolixis raised over time?

    Neurolixis has raised $15K.

  • Who are Neurolixis’s investors?

    United States Department of Defense, Michael J. Fox Foundation, Rett Syndrome Research Trust, and Johnson & Johnson Innovation - JLABS have invested in Neurolixis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »